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Abstract:

Background: Hydroxyurea is underutilized by sickle cell health-care providers in Nigeria despite available evidence of its
effectiveness in reducing the manifestations and complications of sickle cell disease (SCD).
Objectives: To assess the level of utilization and provider-related barriers to the use of hydroxyurea in SCD therapy in Jos,
Nigeria.
Methods: A cross-sectional study conducted among 132 medical doctors providing care for SCD patients. Data on socio-demographics, utilization and barriers to hydroxyurea use were obtained. The barriers were fed cumulatively into the
logistic regression model as predictors of utilization.
Results: Of the 132 care providers, 88 (67%) had been in medical practice for ≥6years. The level of utilization of hydroxyurea was 24.2%. The significant barriers that predicted the non-utilization of hydroxyurea included lack of expertise
(OR=5.1; 95% CI=2.65–9.05), lack of clinical guidelines (OR=3.84; 95% CI=2.37-14.33), fear of side-effects (OR=0.50;
95% CI=0.22–0.68) and doubt about its effectiveness (OR=0.30; 95% CI=0.20–0.90).
Conclusion: The level of utilization of hydroxyurea in the treatment of SCD among the care providers is sub-optimal with
the lack of expertise in its use identified as the most prominent barrier. There is an urgent need for the training of sickle cell
care-providers and the development of clinical guidelines on hydroxyurea use.
Keywords: Hydroxyurea utilization, barriers to hydroxyurea, sickle cell disease, Nigeria.
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Introduction
Sickle-cell disease (SCD) is an inherited blood disorder
that is characterised by ongoing haemolytic anaemia
and recurrent vaso-occlusive events which result in episodic painful crises, organ dysfunctions, poor quality of
life and when untreated, early mortality. 1-3 An estimated
Corresponding author:
Akinyemi OD Ofakunrin,
Department of Paediatrics, University of
Jos / Jos University Teaching Hospital, Jos, Nigeria.
Phone Number: +2348038345783
E-mail Address: aodofak@yahoo.com,
ofakunrina@unijos.edu.ng

African
Health Sciences

765

25 million people are affected globally with the majority
of them living in sub–Saharan Africa where Nigeria accounts for the highest burden of the disease. 4-5
Despite the huge burden of SCD in Nigeria, its treatment has been mainly symptomatic with focus on pain
relief, malaria prophylaxis and folic acid supplementation. 6 However, a disease-modifying therapy for SCD
namely hydroxyurea has been discovered and it is widely available. 7
Hydroxyurea is a ribonucleotide reductase inhibitor that
has been demonstrated by several clinical studies as a
safe and efficacious medication capable of reducing
the manifestations and complications of SCD in both
adults and children.8-11 Globally, it has emerged as a major advancement in the treatment of SCD as it is one
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of the currently approved medications with the capability of modifying the disease process.7 The National Institute of Health (NIH) in 2014 and the British
Society of Haematology in 2018 both recommended
that all patients with the disorder and their family members should be educated about hydroxyurea therapy and
all affected children from age nine months and above
should be offered hydroxyurea regardless of clinical
severity to reduce SCD-related complications and end
organ failure.12, 13
In Nigeria, available reports suggest that the medication
is underutilized by the sickle cell health-care providers
while the barriers to its utilization in the treatment of
SCD among the providers are yet to be elucidated. 6,
14-16
This study, therefore, assessed the level of utilization and barriers to the use of hydroxyurea in the treatment of SCD among the health care-providers in Jos,
North-Central Nigeria.
Materials and methods
Study area
The study was conducted in the four tertiary hospitals
in Jos, Plateau State, North-Central Nigeria. Based on
the 2006 population census, Plateau State had an estimated population of 3.2 million people; and the population of Jos was 736,016.17 The four tertiary health institutions served as referral centres for the provision of
advanced care for SCD patients. The hospitals receive
referrals from various health facilities in Plateau State
and seven neighbouring States. These hospitals are
the Jos University Teaching Hospital (JUTH), Plateau
State specialist hospital (PSSH), Our Lady of Apostles
Hospital (OLAH), and Bingham University Teaching
Hospital (BhUTH). Based on the hospital records, over
2500 patients with SCD are being catered for at these
facilities.

disease patients in the four hospitals who consented to
participate in the study.
Exclusion criteria
Medical doctors who refused to participate in the survey and those who have not attended to any SCD patient in the last twelve months were excluded.
Sample size determination
The sample size for this study was determined using
the appropriate sample size estimation formula for a
cross-sectional study.18 The parameters used included
the standard normal deviate at 95% confidence interval (1.96), q is the complementary probability (1 – p),
d is the precision of the study set at 0.05 and p is the
proportion of doctors with adequate utilization of hydroxyurea in the treatment of SCD patients in a previous similar study which was 9% ( 0.09).19 This gave a
minimum sample size of 132 after 5% of the calculated
sample size was added to cater for non responses, poor
or incomplete responses.

Sampling method
A list of all the medical doctors providing medical
treatment for SCD patients in all the four hospitals was
made giving a total of 242 doctors of which 112 doctors were in JUTH, 57 in PSSH, 22 in OLAH and 51 in
BhUTH. Thereafter, a proportion to size technique was
used to determine the number of doctors that will be
sampled in each of the four hospitals. This was done by
dividing the total number of doctors providing medical
services to SCD patients in each of the hospitals by the
total number of doctors providing medical services to
SCD patients in all the hospitals multiplied by the sample size. Thereafter, a list of all the eligible doctors in all
the hospitals was made and serialized. A computed generated table of random numbers was used to select 61,
28, 31 and 12 doctors from the serialised list of the docStudy population
The study was conducted among medical doctors pro- tors in JUTH, BhUTH, PSSH and OLAH respectively.
viding medical care for SCD patients in the four hospi- Furthermore, the doctors whose number corresponded
tals. In the studied setting, SCD patients are cared for to the one selected by the computer were approached
by the Paediatricians, Haematologists, Family Physicians and sampled until the sample size was met. Data was
collected from each participant using a pretested, strucand General Practitioners.
tured and self-administered questionnaire. The data colStudy design
lected included the socio-demographics, utilization and
This was a cross-sectional study to assess the level of barriers to the utilization/prescription of hydroxyurea.
utilization of hydroxyurea and the barriers to its use in
the treatment of SCD patients. The study was conduct- Data analysis
ed between September and November 2018.
Scoring and grading of responses
In this study, hydroxyurea was considered to have been
Inclusion criteria
‘utilized’, if a provider has prescribed hydroxyurea to
All doctors involved in the medical care of sickle cell any SCD patient in the last 12 months and ‘not utilized’,
African Health Sciences, Vol 21 Issue 2, June, 2021
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if otherwise. The level of utilization of hydroxyurea
was assessed by determining the number of providers
who had prescribed hydroxyurea to their eligible SCD
patients in the last 12 months, and this was also corroborated by determining the proportion of their eligible
patients who are on hydroxyurea. Patients’ eligibility was
based on the 2014 National Institute of Health (NIH)
expert panels’ recommendation and 2018 British Society of Haematology guideline for children and adults
with sickle cell disease. 12, 13 When the proportion of eligible patients on hydroxyurea was greater than 10%, it
was categorised as ‘adequate utilization’ and when it was
equal to or less than 10%, it was regarded as ‘inadequate
utilization’. 19 Ten percent cut off was adopted for the
adequacy of utilization in this study because the level
of uptake of hydroxyurea in Nigeria is still low with
some studies reporting between 0 and 2.6% of eligible
patients being on hydroxyurea. 14-15
The barriers to the utilization of hydroxyurea which
was assessed as explanatory variables included: statement of affirmation of fear of side effects, expertise
in the use of hydroxyurea (this involves being conversant with the dosing regimen, treatment monitoring and
management of possible side effects), availability of
clinical guidelines, cost of medication and monitoring
of treatment, doubt about the effectiveness of hydroxyurea, perception of patients refusal etc. In order to reduce recall / information bias, the research questions
were carefully selected and the duration for the recall
of prescription of hydroxyurea was restricted to a maximum of 12 months.

statistical analysis was carried out on qualitative variables such as sex, speciality, cadre etc of the respondents.
These and other explanatory variables such as the provider-related barriers were presented in frequency tables and expressed in frequencies and percentages. The
barriers were fed cumulatively into the logistic regression model as predictors of utilization of hydroxyurea.
Chi-square test was used to test the association between
some demographic characteristics of the respondents
and utilization of hydroxyurea. Adjusted odds ratio and
95% confidence interval were used as point and interval
estimates respectively with a P-value of <0.05 considered statistically significant.
Ethical considerations
Ethical approval (JUTH/DCS/ADM/127/XVIII/1156) was obtained from the Health Research Ethicsal Committee of the Jos University Teaching Hospital. Permission was sought and gotten from the various
heads of the participating hospitals and departments.
Written informed consent was sought and obtained
from every respondent before enrolment into the study.
Assurance of anonymity and confidentiality of all information supplied was also given.

Results
Socio-Demographic Characteristics
A total of 132 medical doctors who had been providing
medical care for sickle cell disease patients participated
in this study. Seventy-four (56.1%) of the respondents
were males while 58 (43.9%) were females. Sixty-one
(46.2%) of the respondents were family physicians
while paediatricians and haematologists accounted for
Statistical analysis
All the returned questionnaires were reviewed for com- 13.6% and 8.3% respectively. Eighty-eight (67%) of the
pleteness and thereafter serialized in preparation for studied population had been in medical practice for updata entry. Data analysis was carried out using SPSS ver- ward of six years while 80 (60.6%) of them affirmed to
sion 23.0 for Windows (SPSS, Chicago, IL). Descriptive have attended to more than ten SCD patients in the last
6 months (Table 1).
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Table 1: Demographic characteristics of the respondents
Variable

Frequency (n=132)

Percentage (100.0)

Sex
Male
Female

74
58

56.1
43.9

Speciality
Paediatrics
Family medicine
Haematology

18
61
11

13.6
46.2
8.3

General Practice

42

31.8

Cadre
Medical officers
Resident doctors
Consultants

51
52
29

38.6
39.4
22.0

Years of practice
1- 5years
6 -10 years
>10 years

44
46
42

33.4
34.8
31.8

Facility of practice
JUTH
BhUTH
PSSH
OLAH

61
28
31
12

46.2
21.2
23.5
9.1

Number of SCD patients
seen in the last 6 months
1-5
6-10

22
30

16.7
22.7

>10

80

60.6

Categories of patient seen
Children only
Adults only
Both

18
16
98

13.6
12.1
74.3

JUTH- Jos University Teaching Hospital, BUTH – Bingham University Teaching Hospital, Plateau
State Specialist Hospital, OLAH – Our Lady of Apostle Hospital

Utilization of hydroxyurea in the treatment of
sickle cell disease patients
Ninety-three (70%) of the respondents had never discussed hydroxyurea as a treatment option with any SCD
patient. About two-thirds (65.9%) of the respondents
admitted that they lacked or had poor expertise in the

African Health Sciences, Vol 21 Issue 2, June, 2021

use of hydroxyurea for the treatment of sickle cell
disease while only 32 (24.2%) of the respondents had
prescribed hydroxyurea for the treatment of sickle cell
disease in the last 12 months. Only 13 (9.8%) of the
providers had >10% of their eligible patients on hydroxyurea (Table 2).
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Table 2: Utilization of hydroxyurea in the treatment of sickle cell disease patients among all
the respondents
Variable

Frequency

Percentages

n=132
Ever discussed hydroxyurea as a treatment
option with any SCD patient
Yes
No

39
93

29.5
70.5

Expertise in the use of hydroxyurea
Good
Fair
Poor/None

11
34
87

8.3
25.8
65.9

Prescribed hydroxyurea in the last 12 months
Yes
No

32
100

24.2
75.8

Proportion of eligible SCD patients on
hydroxyurea
None
100
<5%
11
5 – 10%
8
11-50%
13
>50%
0

75.8
8.3
6.1
9.8
0.0

Utilization of hydroxyurea
Utilized
Not utilized

32
100

24.2
75.8

Adequacy of utilization
Adequate

13

9.8

Inadequate

119

90.2

Comparison of the utilization of hydroxyurea by
speciality, cadre and years of practice
Table 3 shows the utilization of hydroxyurea based on
speciality, cadre and years of practise among the study
participants. The proportion of haematologists (81.8%)
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and paediatricians (72.7%) who had prescribed hydroxyurea within the last 12 months were more than the proportions of family physicians (13.1%) and the general
practitioners (4.8%) and the difference was statistically
significant (p< 0.0001) (Table 3).
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Table 3: Comparison of the utilization of hydroxyurea by speciality, cadre,
and years of practice.
Variable

Utilized n (%)

Not utilized n

Total

χ2

P-value

55.2

<0.0001

(%)
Speciality
Paediatrics
Family medicine

13(72.2)
8(13.1)

5(27.8)
53(86.9)

18
61

Haematology

9(81.8)

2(18.2)

11

General Practice

2 (4.8)

40(95.2)

42

32

100

132

Cadre
Medical officers
Resident doctors

2(3.9)
22(42.3)

49(96.1)
30(57.7)

51
52

Consultants

8(27.6)

21(72.4)

29

32

100

132

3(6.8)

41(93.2)

44

5 -10 years

18(39.1)

28(60.9)

46

>10 years

11(26.2)

31(73.8)

42

32

100

132

Total

Total
Years of practice
1-5years

Total

Among the different cadres, the proportion of resident
doctors (42.3%) who utilized hydroxyurea was more
than the other cadres (3.9% and 27.6%- medical officers and consultants respectively) and the difference
was statistically significant (p<0.0001).
Provider-related barriers to the utilization of hydroxyurea
Lack of expertise was the most frequent barrier to the

20.88 <0.0001

12.91 0.002

use of hydroxyurea for the treatment of SCD as 86
(65.2%) of the respondents expressed this as a barrier. Other main barriers identified among the respondents included lack of clinical guidelines on hydroxyurea
use (56.1%), fear of side effects (37.1%), and 22% expressed doubt about the effectiveness of hydroxyurea
in achieving desired treatment outcomes as a barrier
(Table 4).

Table 4: Providers-related barriers to the utilization of hydroxyurea

Variables

Frequency

Percentage

Lack of expertise in hydroxyurea use

86

65.2

Lack of clinical guidelines on hydroxyurea use

74

56.1

Fear of side effects

49

37.1

Doubt about the effectiveness of hydroxyurea
Patient did not meet the criteria for initiating the

29
25

22.0
18.9

Perception of patients refusal

23

17.4

Fear of poor adherence to medication by the

16

12.1

patients
Not usually comfortable treating SCD patients

8

6.1

Cost of medication and monitoring of treatment

5

3.8

treatment

NB – There were multiple responses
SCD – Sickle cell disease

African Health Sciences, Vol 21 Issue 2, June, 2021
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Factors influencing the non-utilization of hydroxyurea
The odds of non-utilization of hydroxyurea was 5.1
times higher in providers with no expertise in its use
compared to those with some level of expertise (OR
=5.1; 95% CI =2.65–9.05; P<0.0001). Similarly, the
odds of non-utilization of hydroxyurea was 3.8 times

higher among providers who did not have clinical
guidelines on hydroxyurea use compared to those who
had (OR =3.84; 95% CI =2.37-14.33). Other barriers that predicted the non-utilization of hydroxyurea included fear of side-effects (OR =0.50; 95% CI
=0.22–0.68; P=0.019) and doubt about its effectiveness
in SCD management (OR =0.30; 95% CI =0.20–0.90;
P=0.002). (Table 5).

Table 5: Factors influencing the non-utilization of hydroxyurea in the study population
Variables

Odds ratio

95% CI

P-value

Speciality
Paediatrics
Family medicine

1.570
1.634

0.010 – 3.765
0.015 – 1.784

0.766
0.687

Haematology

0.200

0.100 – 0.900

General Practice

1

-

0.004
-

Cadre
Resident doctors

2.20

0.179 – 5.053

0.355

Medical officers

0.90

0.725 – 1.010

0.213

1

-

-

0.50
1

0.215 - 0.684
-

0.019

5.05
1

2.647 – 9.048

<0.0001

3.84
1

2.366 - 14.335
-

<0.0001

0.30

0.200 - 0.901

0.002

1
0.26

0.194 - 1.869

0.200

0.69

0.349 – 4.958

0.451

1.30

0.318 – 9.076

0.759

1.07

0.780 – 5.420

0.887

0.94

0.459 – 4.995

0.919

Consultants
Barriers
Fear of side effects
Absent
Present
Expertise in the use of
hydroxyurea in SCD
Absent
Present
Lack
of
clinical
guidelines
on
hydroxyurea use
Yes
No
Effectiveness of
hydroxyurea
Not doubtful
Doubtful
Perception of patients
refusal
Fear of poor patients’
medication adherence
Not comfortable treating
SCD patients
Patient did not meet the
criteria for initiating
therapy
Cost of medication and
monitoring of treatment

Discussion
The level of utilization of hydroxyurea by the providers
in this study was low, as only about a quarter of the
respondents reported its use within the last 12 months.
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Besides, only a few of the respondents ‘adequately’ utilized hydroxyurea in the management of their SCD patients. This level of utilization (24.2%) is higher than the
level reported in the studies conducted in Zaria, Nigeria
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in 2007 and 2017 where abysmally low levels of utilization of 0% and 2.6% respectively were reported. 14-15
The level is however lower than those reported in the
studies conducted in the United States.19-20 Our finding
implies that most of the eligible patients are being denied the opportunity of receiving this disease-modifying
therapy. Consequently, these patients could be at risk of
more frequent sub-clinical and clinical vaso-occlusive
events and haemolysis which could result in frequent
painful crises, hospital admissions, early complications
including irreversible organ damages and poor quality
of life. 1-3 The reason for the low level of utilization
of hydroxyurea in this study may be due to poor knowledge among the respondents as about two-thirds of the
interviewed providers self-reported poor or no expertise in the use of hydroxyurea. A previous study had
identified poor provider knowledge as a reason for the
low level of utilization of therapies among sickle cell
disease patients.21 Also, in contrast to our study, the design in the US surveys focused mainly on specialist care
providers (haematologists) who most probably must
have had the requisite training and retraining as well as
established protocol on the use of hydroxyurea.22 However, in most low–middle-income countries, there is a
dearth of specialist care providers and hence the need
for training of more health care providers (non-haematologists) to boost the skilled manpower needed to
reduce the burden of this disease by filling the gap.23, 24
Furthermore, some barriers were reported by the respondents to have affected the utilization of hydroxyurea in the treatment of their patients.
This study found that the most common barrier to the
utilization of hydroxyurea among the respondents was
the lack of expertise in its use in the treatment of sickle
cell disease. The lack of expertise involves the aspect of
dosing regimen, monitoring and management of possible side effects in the prospective patients. The National
Institutes of Health Consensus Development Conference Statement on Hydroxyurea had similarly identified
‘limited number of physicians who have expertise in the
use of hydroxyurea for sickle cell disease’ as a barrier.23
This finding implies that continuous medical education
and capacity development should be regularly provided
for doctors who care for sickle cell disease patients to
keep them abreast of the developments and tools that
could be beneficial to their patients.
Lack of clinical guidelines on the use of hydroxyurea in
the treatment of sickle cell disease was also identified
as a barrier in this study. This is in synergy with the
findings from recent studies which acknowledged the
African Health Sciences, Vol 21 Issue 2, June, 2021

lack of treatment guidelines as a barrier to the use of
hydroxyurea, especially in low-resource countries. 25, 26
The development of clinical guidelines could help to
standardize practice, boost the confidence and enhance
the expertise of the physicians. It is worth noting that
there’s an on-going effort by the Sickle Cell Disease
Stroke Prevention in Nigeria (SPIN) trial towards establishing local clinical guidelines for hydroxyurea use, especially for stroke prevention.27 Furthermore, as it has
been reported in previous studies, fear of side effects
of hydroxyurea was another reason for not prescribing
hydroxyurea by this study’s participants.23, 25, 28 Some of
the side effects reported in order of concern were bone
marrow suppression, carcinogenicity and infertility. It
has been well documented that the bone marrow suppressive effect of hydroxyurea is dose-dependent and
easily reversible with no life-threatening event reported
from its occurrence providing adequate monitoring is
instituted. 11, 29, 30 Consequently, provision of adequate
monitoring by the health care providers requires that
they have requisite knowledge and expertise in the use
of hydroxyurea for SCD management. Similarly, hydroxyurea at therapeutic dosage has not been reported
to be associated with an increased risk of cancer among
sickle cell disease patients who are on the medication
compared to those not on it or the general population.31
Therefore, it will be unjustifiable to withhold beneficial
treatment from the patients on account of inference
that is not evidence-based. Regarding infertility, sickle
cell disease has been associated with infertility especially
in males. Also, a few studies have reported the contribution of hydroxyurea treatment to male infertility.32 However, the area of reproductive epidemiology in sickle
cell disease is vastly understudied and requires further
research to obtain concrete evidence.32 Nevertheless,
the risk of untreated SCD cannot be compared to the
risk associated with HU therapy, especially in low-middle-income countries. Therefore, HU use appears to be
highly justified. Doubts about the drug’s effectiveness
were also found to have constituted a significant barrier
to its use. This finding is similar to what was reported by
a study conducted among haematologists/oncologists
in Florida and North Carolina.33 Local studies on the effectiveness and safety of hydroxyurea may be needed to
remove this barrier and allay the fear of toxicity of this
medication in low- middle –income countries.11 Finally, the cost of the medication and monitoring of therapy was reported as a barrier by a few of the respondents. This may, nonetheless, be a very important barrier
among the patients, especially in low resource countries,
and it’s worth exploring through a further research.
772

We are not unmindful that our study, being a cross-sectional survey, may be limited by the possibility of recall
bias. Also, the availability of facilities for hydroxyurea
treatment monitoring could also constitute a barrier to
its prescription but this was not assessed in this study.
Conclusion
The level of utilization of hydroxyurea by the providers
in this study was low. Lack of expertise in the use of
hydroxyurea in the treatment of sickle cell disease was
the most important barrier preventing the doctors from
utilizing/prescribing hydroxyurea to their patients. Other identified significant barriers included lack of clinical
guidelines on hydroxyurea use in sickle cell disease, fear
of side effects and doubt about the effectiveness of the
drug.
The information from this survey has provided some
insights into the barriers to the utilization of hydroxyurea in a low-middle income setting. The barriers need to
be addressed so that SCD patients could benefit from
this life-saving and disease-modifying therapy. There
is, therefore, an urgent need to engage the sickle cell
care-providers in training on the use of hydroxyurea
in the therapy of SCD as well as the development of
clinical guidelines. The training could be done within
the framework of local practice, thereby providing the
local capacity necessary to expand the safe use of hydroxyurea.
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